Shares of Viveve Medical, Inc. (NASDAQ:VIVE) were down 6.2% on Friday after the company announced weaker than expected quarterly earnings. The company traded as low as $6.43 and last traded at $6.61, with a volume of 585,793 shares traded. The stock had previously closed at $7.05.

The company reported ($0.54) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by $0.21. Viveve Medical had a negative return on equity of 232.94% and a negative net margin of 255.11%. The business had revenue of $3.08 million during the quarter, compared to analysts’ expectations of $3.24 million. During the same period in the previous year, the business earned ($0.66) EPS. The business’s revenue was up 97.4% compared to the same quarter last year.

A number of analysts recently commented on VIVE shares. B. Riley reaffirmed a “buy” rating and issued a $10.00 price target on shares of Viveve Medical in a research note on Wednesday, May 17th. Maxim Group reaffirmed a “buy” rating and issued a $11.00 price target on shares of Viveve Medical in a research note on Friday. ValuEngine raised Viveve Medical from a “sell” rating to a “hold” rating in a research note on Friday, June 9th. Raymond James Financial, Inc. started coverage on Viveve Medical in a research note on Thursday, May 25th. They issued an “outperform” rating and a $10.00 price target for the company. Finally, Cowen and Company started coverage on Viveve Medical in a research note on Wednesday, May 3rd. They issued an “outperform” rating and a $11.00 price target for the company. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $12.80.

Hedge funds have recently made changes to their positions in the company. Rhumbline Advisers acquired a new stake in shares of Viveve Medical during the second quarter worth approximately $110,000. JPMorgan Chase & Co. acquired a new stake in shares of Viveve Medical during the second quarter worth approximately $151,000. Schwab Charles Investment Management Inc. acquired a new stake in shares of Viveve Medical during the second quarter worth approximately $189,000. Teachers Advisors LLC acquired a new stake in shares of Viveve Medical during the second quarter worth approximately $196,000. Finally, TIAA CREF Investment Management LLC acquired a new stake in shares of Viveve Medical during the second quarter worth approximately $296,000. 61.75% of the stock is owned by institutional investors.

The firm’s market capitalization is $127.93 million. The company has a 50 day moving average price of $7.06 and a 200 day moving average price of $6.44.

WARNING: “Viveve Medical, Inc. (VIVE) Stock Price Down 6.2% on Disappointing Earnings” was posted by Daily Political and is owned by of Daily Political. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://www.dailypolitical.com/2017/08/11/viveve-medical-inc-vive-stock-price-down-6-2-on-disappointing-earnings.html.

Viveve Medical Company Profile

Viveve Medical, Inc designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories.

Receive News & Ratings for Viveve Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.